NCT05820698Completed
The Mediterranean Diet and Time-Restricted Eating Dietary Interventions for Psoriasis Study
A Feasibility Pilot Study Examining the Effect of a Mediterranean Style Diet and Time-restricted Eating on Individuals With Mild-moderate Psoriasis
Source: ClinicalTrials.gov · Last updated 4 May 2025
Brief summary (registry, in English)
The METRED-P study will test the feasibility of implementing a Mediterranean style diet and/or time-restricted eating as dietary patterns in individuals with psoriasis. This study will address the following research questions: 1. Are participants' able to adhere to the allocated dietary intervention? 2. What is the participants' acceptability of the allocated dietary intervention? 3. What is the practicality (from a clinician's stand point) of delivering the dietary interventions? 4. When adhering to the allocated intervention, are there changes in psoriasis severity? 5. When adhering to the allocated intervention, are there changes in measures of body composition? 6. When adhering to the allocated intervention, are there changes in fasting blood measures? Participants will attend an initial clinic visit for a fasting blood sample, psoriasis examination, body composition measurements, and will complete short multiple-choice questionnaires on the severity of their psoriasis. A Research Nutritionist will deliver the diet interventions as diet consultation sessions. These sessions are reoccurring throughout the study as virtual consultation booster sessions, which are supplemented with wellbeing check-in calls. Participants will complete short questionnaires on the severity of their psoriasis and will record their dietary intake for 4 days, before the start of the study, and on week 1, week 6, and week 12 of the study. The allocated diet should be adhered to for 12 weeks until the end of the study, where participants will return and attend a final clinic visit to repeat the measures obtained during the initial clinic visit. Researchers will compare the feasibility of implementing a Mediterranean style diet and a Mediterranean style diet with time-restricted eating, with a UK diet with time-restricted eating.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 22 (actual)
- First submitted
- 16 Mar 2023
- Start date
- 8 Jun 2023
- Primary completion date
- 2 Oct 2024
- Lead sponsor
- King's College London
- Diseases
- Psoriasis
- NCT number
- NCT05820698
What you commit to
- Study type: Interventional
- Participants enrolled: 22
- From 8 Jun 2023 to the primary completion date, 2 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- is receiving or has received photo (light) therapies for psoriasis in the past 3 months
- taking medication likely to interfere with study outcomes e.g. steroids (except occasional use of inhalers), anti-inflammatories or immune-suppressive drugs
- taking blood pressure medication, but has not been on a stable dosage during the last 3 months
- currently participating in a pharmaceutical study for psoriasis treatments (topical, light, tablet, or injection therapies) or has participated in a pharmaceutical study \< 3 months ago
Other illness
- diagnosis of a gluten, nut, peanut, fish, or shellfish allergy
- is or has been diagnosed in the past with any of the following:
- Anaemia
- Asthma
- Cancer in the last five years (except non-melanoma skin cancer)
- Cardiovascular disease (angina, congenital heart disease, coronary artery disease, heat attack, heart failure or stoke)
- Chronic gastrointestinal disease (Crohn's disease, ulcerative colitis, celiac disease or malabsorption diseases)
- Chronic kidney disease
- Dementia
- Eating disorders (anorexia, bulimia or binge eating disorder)
- Insulin dependent diabetes
- Liver disease
- Lupus
- Multiple sclerosis
- Rheumatoid arthritis
- Thyroid disease
- history of bariatric surgery
- history of substance abuse or alcoholism (past history of alcohol intake \>60 units/men or 50 units/women), within the last 12 months
Other
- is taking Cyclosporine or Stelara in the past 3 months
- is a shift worker or is involved in shift work
- is planning on international travel during the study period
- is not weight stable or has attempted to lose weight during the past 6 months
- diagnosis of a gluten or dairy intolerance
- is following a restrictive diet/restricting food groups i.e vegan, vegetarian, gluten-free , or a Mediterranean style diet
- is following any intermittent fasting regimes inclusive of 5:2, alternate day fasting or modified alternate day fasting, time-restricted eating over the past 6 months
- reports a habitual eating window \< 12 h per day
- reports a baseline healthy diet (e.g. \> 5 servings of fruits and vegetables per day, 1 serving of nuts per day , 2 servings of whole grains per day, 2 servings of fish per week, \> 1 servings of nuts per day and rarely eats sweet snacks, cakes, fried foods and red meat).
- taking fish oil or other dietary supplements (except daily multivitamins providing no more than 200% of UK dietary recommended values)
- currently pregnant, currently breastfeeding or planning to become pregnant in the next 4 months
- not on a stable topical treatment regimen for psoriasis (if prescribed)
- currently participating in another diet intervention study or has participated in a diet intervention study \< 3 months ago
- unwilling to record dietary intakes using handwritten diet diaries
- not fluent in the English language
- reports to have fainted in the past during an intravenous blood test
Who the study is looking for
- adults (aged 18 years or older)
- a medical diagnosis of plaque psoriasis
- a baseline Psoriasis Area Severity Index score between 5-10 (evaluated during screening)
- a Body Mass Index between 20-40
- not on tablet or injection therapies for psoriasis, OR if on tablet or injection therapies, is 6 months stable on the same dose of tablet or injection therapies
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Metabolic Research Unit, Franklin-Wilkins Building, King's College London. 150 Stamford Street, Waterloo, London. Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.